J&J, Genmab win FDA AdCom backing for multiple myeloma therapy

7 hours ago 1

J&J (NYSE:JNJ) announced Wednesday that an FDA advisory committee, which reviews cancer drugs, voted in favor of Darzalex Faspro, an antibody therapy the company has developed with Genmab (GMAB) for a type of blood cancer called smoldering multiple myeloma.
During

Recommended For You